Lonza Group Ag Debt to Equity Ratio 2012-2024 | LZAGY
Current and historical debt to equity ratio values for Lonza Group Ag (LZAGY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Lonza Group Ag debt/equity for the three months ending December 31, 2024 was 0.45.
| Lonza Group Ag Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-12-31 | $11.75B | $10.66B | 1.10 |
| 2024-06-30 | $9.37B | $10.41B | 0.90 |
| 2023-12-31 | $8.17B | $10.60B | 0.77 |
| 2023-06-30 | $8.12B | $11.54B | 0.70 |
| 2022-12-31 | $7.01B | $11.18B | 0.63 |
| 2022-06-30 | $6.89B | $10.45B | 0.66 |
| 2021-12-31 | $7.26B | $10.75B | 0.68 |
| 2021-06-30 | $8.59B | $8.06B | 1.07 |
| 2020-12-31 | $8.05B | $7.34B | 1.10 |
| 2020-06-30 | $7.69B | $6.79B | 1.13 |
| 2019-12-31 | $7.32B | $6.61B | 1.11 |
| 2019-06-30 | $7.23B | $6.23B | 1.16 |
| 2018-12-31 | $7.80B | $6.43B | 1.21 |
| 2018-06-30 | $7.71B | $6.50B | 1.19 |
| 2017-12-31 | $7.66B | $6.36B | 1.21 |
| 2017-06-30 | $4.35B | $5.39B | 0.81 |
| 2016-12-31 | $4.54B | $2.39B | 1.90 |
| 2016-06-30 | $4.37B | $2.12B | 2.07 |
| 2015-12-31 | $4.28B | $2.22B | 1.93 |
| 2015-06-30 | $4.34B | $2.08B | 2.09 |
| 2014-12-31 | $4.72B | $2.33B | 2.02 |
| 2014-06-30 | $5.09B | $2.34B | 2.18 |
| 2013-12-31 | $4.77B | $2.30B | 2.08 |
| 2013-06-30 | $5.15B | $2.28B | 2.26 |
| 2012-12-31 | $5.01B | $2.57B | 1.95 |
| 2012-06-30 | $4.99B | $2.52B | 1.98 |
| 2011-12-31 | $5.28B | $2.67B | 1.98 |
| 2011-06-30 | $2.60B | $2.46B | 1.06 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $50.320B | $7.468B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.616B | 27.97 |
| Boston Scientific (BSX) | United States | $153.611B | 38.46 |
| Stryker (SYK) | United States | $149.817B | 31.33 |
| EssilorLuxottica (ESLOY) | France | $128.259B | 0.00 |
| Medtronic (MDT) | Ireland | $112.441B | 15.94 |
| Haleon (HLN) | United Kingdom | $45.596B | 26.03 |
| ResMed (RMD) | United States | $37.597B | 28.24 |
| GE HealthCare Technologies (GEHC) | United States | $34.163B | 16.22 |
| Agilent Technologies (A) | United States | $33.875B | 22.08 |
| Terumo (TRUMY) | Japan | $24.770B | 32.17 |
| Koninklijke Philips (PHG) | Netherlands | $22.956B | 16.11 |
| Insulet (PODD) | United States | $21.162B | 83.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.315B | 11.76 |
| Baxter (BAX) | United States | $15.236B | 11.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.113B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.723B | 23.40 |
| Lantheus Holdings (LNTH) | United States | $5.479B | 13.82 |
| Prestige Consumer Healthcare (PBH) | United States | $3.900B | 17.42 |
| Perrigo (PRGO) | Ireland | $3.676B | 9.32 |
| Haemonetics (HAE) | United States | $3.609B | 16.44 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.334B | 27.70 |
| ICU Medical (ICUI) | United States | $3.192B | 23.54 |
| QuidelOrtho (QDEL) | United States | $1.976B | 13.59 |
| LeMaitre Vascular (LMAT) | United States | $1.875B | 41.91 |
| AtriCure (ATRC) | United States | $1.561B | 0.00 |
| Acuren (TIC) | United States | $1.375B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.248B | 12.67 |
| Phibro Animal Health (PAHC) | United States | $1.212B | 15.49 |
| Green Thumb Industries (GTBIF) | United States | $1.163B | 26.16 |
| Neogen (NEOG) | United States | $1.081B | 13.83 |
| BioLife Solutions (BLFS) | United States | $1.036B | 0.00 |
| InMode (INMD) | Israel | $0.954B | 9.62 |
| Kestra Medical Technologies (KMTS) | United States | $0.757B | 0.00 |
| Owens & Minor (OMI) | United States | $0.669B | 5.55 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.662B | 0.00 |
| CeriBell (CBLL) | United States | $0.622B | 0.00 |
| Evolus (EOLS) | United States | $0.589B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.553B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.507B | 0.00 |
| Valneva SE (VALN) | France | $0.488B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.452B | 0.00 |
| Surmodics (SRDX) | United States | $0.424B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.360B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.344B | 12.67 |
| SNDL (SNDL) | Canada | $0.326B | 0.00 |
| Quanterix (QTRX) | United States | $0.315B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.284B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| ZimVie (ZIMV) | United States | $0.263B | 11.94 |
| Sanara MedTech (SMTI) | United States | $0.259B | 0.00 |
| Brainsway (BWAY) | Israel | $0.253B | 66.85 |
| Aurora Cannabis (ACB) | Canada | $0.249B | 73.83 |
| Cresco Labs (CRLBF) | United States | $0.247B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.228B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.221B | 0.00 |
| Biote (BTMD) | United States | $0.218B | 6.14 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Organigram Global (OGI) | Canada | $0.186B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.13 |
| Omeros (OMER) | United States | $0.180B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.173B | 0.00 |
| Exagen (XGN) | United States | $0.148B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.147B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.129B | 15.90 |
| Apyx Medical (APYX) | United States | $0.098B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 12.37 |
| Jin Medical (ZJYL) | China | $0.090B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.088B | 0.00 |
| MacroGenics (MGNX) | United States | $0.086B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| Zynex (ZYXI) | United States | $0.076B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.070B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.062B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 58.29 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Safety Shot (SHOT) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.10 |
| Rockwell Medical (RMTI) | United States | $0.027B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |